Regeneron’s Antibody Gets Updated FDA Nod
- ByTipRanks-
Regeneron Pharmaceuticals’ (NASDAQ: REGN) investigational COVID-19 antibody cocktail, REGEN-COV (casirivimab and imdevimab), has received updated authorization for emergency use...
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Regeneron Pharmaceuticals Inc (REGN)
577.13
+2.52(+0.44%)
After Hours
577.13
0.00(0.00%)
- Real-time Data
- Volume:362,192
- Bid/Ask:570.30/585.15
- Day's Range:570.38 - 580.87
REGN Overview
- Prev. Close
- 577.13
- Day's Range
- 570.38-580.87
- Revenue
- 9.2B
- Open
- 577.12
- 52 wk Range
- 441.3-657.24
- EPS
- 35.35
- Volume
- 362,192
- Market Cap
- 59.77B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 737,567
- P/E Ratio
- 16.33
- Beta
- 0.13
- 1-Year Change
- -8.69%
- Shares Outstanding
- 103,556,326
- Next Earnings Date
- Aug 05, 2021
What is your sentiment on Regeneron Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.
Regeneron Pharmaceuticals Inc News
- FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
- ByBenzinga-
Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the investigational COVID-19 antibody...
- Regeneron wins expanded authorization from FDA for COVID-19 antibody cocktail
- BySeeking Alpha-
Regeneron Pharmaceuticals announced that the FDA has updated the Emergency Use Authorization ((EUA)) for its COVID-19 antibody cocktail REGEN-COV (casirivimab and...
Regeneron Pharmaceuticals Inc Analysis
- Regeneron: Rapid Growth Seems To Be On A Pause
- BySeeking Alpha-
- Regeneron: Only 1 Year Of High Growth Left
- BySeeking Alpha-
- A Comprehensive Guide to Genomic ETFs
Scientists across the world are researching some inconceivable biological concepts like creating a gene-edited human baby or a human-animal hybrid embryo or curing diabetes and...
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Sell | Sell | Sell | Strong Buy |
| Summary | Strong Buy | Neutral | Sell | Neutral | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,697.10 | 2,706.70 | 2,675.90 | +2.6 | +0.10% | 1.08M | NASDAQ | |||
| 351.95 | 359.40 | 350.74 | -4.35 | -1.22% | 13.18M | NASDAQ | |||
| 200.09 | 202.07 | 196.25 | +4.90 | +2.51% | 17.89M | NYSE | |||
| 36.62 | 39.08 | 36.54 | -1.48 | -3.88% | 21.80M | NYSE | |||
| 197.50 | 199.61 | 193.61 | +2.51 | +1.29% | 21.74M | NASDAQ | |||
| 53.68 | 54.47 | 53.53 | -0.04 | -0.07% | 18.10M | NASDAQ | |||
| 423.61 | 425.05 | 419.98 | +1.84 | +0.44% | 211.64K | NYSE | |||
| 35.20 | 38.48 | 35.01 | -1.82 | -4.92% | 59.06M | NYSE | |||
| 43.31 | 43.75 | 43.26 | -0.41 | -0.94% | 3.09M | NYSE | |||
| 239.79 | 242.48 | 238.37 | -1.75 | -0.72% | 1.85M | NASDAQ | |||
| 235.40 | 240.38 | 233.80 | -1.18 | -0.50% | 2.15M | NASDAQ | |||
| 100.60 | 107.21 | 100.43 | -3.00 | -2.90% | 24.89M | NYSE | |||
| 43.96 | 44.14 | 43.25 | +1.15 | +2.69% | 43.07M | NYSE | |||
| 11.64 | 11.71 | 11.60 | +0.11 | +0.95% | 3.24M | NASDAQ | |||
| 28.37 | 28.57 | 27.92 | +0.25 | +0.89% | 16.73K | OTC Markets |
Regeneron Pharmaceuticals Inc Company Profile
Regeneron Pharmaceuticals Inc Company Profile
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Read More
- 2021-08-02 11:00:02Regn sets to reach its peak👍
- 2021-05-13 13:35:17
As far as i can see, insiders are exercising cheap options to sell immediately for good profit; but there’s no one of the board buying at the market, to give some confidence on the company; to myself it’s a pity of time and wasted capital stuck on this - 2021-05-07 13:02:26possibly acquiring Inovio?
- 2021-05-11 16:00:30They shouldn’t; then the 500$ line will be lost forever
- 2021-05-06 11:52:50490.08
- 2021-05-06 10:50:30483.75
- 2021-05-06 10:45:47hello
- 2021-05-06 10:44:41100
- 2021-05-06 10:42:56
hello - 2021-05-06 10:42:53I smell billions
- 2021-05-06 10:42:43hi
- 2021-05-06 10:41:44700
- 2021-05-06 10:41:11500
- 2021-05-03 10:24:07
topped just above 500 and down back to 480, what's next?- 2021-05-05 21:44:25earnings tomorrow ;)
- 2021-04-26 14:24:12
I bought @470 I'll comeback to discuss more at @600 :))) - 2021-04-24 17:21:37Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents. Do some good and get rich
- 2021-04-22 13:49:07digipharm going to be big check it out
- 2021-04-21 15:35:42Quick buy call on SNDX pharma with 20% upside cap today..17.5 call option target 5$
- 2021-04-21 10:16:14
EPS forecast is going to 'double' to 16 !! (august earnings) . go go go - 2021-03-30 09:26:14Going up !! Target 640!
- 2021-04-20 13:13:05Whwre you see that
- 2021-04-21 10:17:39earnings, analists, news, ... read read read
- 2021-03-23 08:02:52Clinical phae 3 data was just released, showing that 50% dose of REG-COV is also effective, even 12.5% works... This should significantly increase the revenue they can tap from the antibody cure, now that the numbers are surging all over Europe
- 2021-02-28 12:09:01Do they pay dividends?
- 2021-03-01 00:07:44nopp
- 2021-02-24 18:25:03Heading south, ey?
- 2021-02-24 08:58:23did we hit bottom yet?
- 2021-02-19 18:52:47why is it going down for weeks ?
- 2021-02-22 14:31:06ARKG is buying REGN now to hedge against a correction and sell them to buy more growth stock when that happens. However the valuation is indeed quite attractive.
- 2021-02-19 18:52:11why is it going down fir weeks ?
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.